Other formats:
BibTeX
LaTeX
RIS
@article{1805161,
author = {Holická, Martina and Vysloužil, Jakub and Kubová, Kateřina and Muselík, Jan and Vetchý, David},
article_location = {Praha},
article_number = {10},
keywords = {GnRH analogues; GnRH agonist; GnRH antagonist; hormones; therapy},
language = {cze},
issn = {0009-2770},
journal = {CHEMICKÉ LISTY},
title = {Gonadoliberin (gonadotropin uvolňující hormon), jeho agonisté a antagonisté},
url = {http://www.chemicke-listy.cz/ojs3/index.php/chemicke-listy/article/view/3933/3844},
volume = {115},
year = {2021}
}
TY - JOUR
ID - 1805161
AU - Holická, Martina - Vysloužil, Jakub - Kubová, Kateřina - Muselík, Jan - Vetchý, David
PY - 2021
TI - Gonadoliberin (gonadotropin uvolňující hormon), jeho agonisté a antagonisté
JF - CHEMICKÉ LISTY
VL - 115
IS - 10
SP - 516-523
EP - 516-523
PB - CHEMICKE LISTY
SN - 00092770
KW - GnRH analogues
KW - GnRH agonist
KW - GnRH antagonist
KW - hormones
KW - therapy
UR - http://www.chemicke-listy.cz/ojs3/index.php/chemicke-listy/article/view/3933/3844
N2 - Nowadays, analogues of gonadotropin-releasing hormone are among the standard drugs in several indications, often using modern dosage forms. Globally, their market is estimated at billions of $ annually. This review article summarizes basic information on the relationship between structure and effect, pharmacology, and application of gonadotropin-releasing hormone and its synthetic analogues. Due to their properties, namely a higher efficiency and a higher binding affinity for the gonadotropinreleasing hormone receptor compared to native gonadotropin releasing hormone, the analogues have found applications in the treatment of many diseases, where it is necessary to suppress the secretion of gonadotropins and sex hormones. They are usually indicated for the treatment of cancers of various origins, premature puberty or artificial insemination. Due to their peptide nature, they are not administered orally, but require injection or intranasal administration. Compared to agonists, antagonists show faster onset of action and the absence of the so-called flareup phenomenon, i.e., temporarily increased serum levels of lutropin, follitropin and, consequently, of testosterone and estradiol.
ER -
HOLICKÁ, Martina, Jakub VYSLOUŽIL, Kateřina KUBOVÁ, Jan MUSELÍK and David VETCHÝ. Gonadoliberin (gonadotropin uvolňující hormon), jeho agonisté a antagonisté (Gonadoliberin (Gonadotropin-Releasing Hormone), Its Agonists and Antagonists). \textit{CHEMICKÉ LISTY}. Praha: CHEMICKE LISTY, 2021, vol.~115, No~10, p.~516-523. ISSN~0009-2770.
|
